查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010043

動物用藥品市場：2026-2032年全球市場預測（依產品類型、目標動物、給藥途徑、疾病類型、最終用戶和分銷管道分類）

Animal Pharmaceuticals Market by Product Type, Species, Route of Administration, Disease Type, End User, Distribution Channels - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年動物用藥品市值為457.4億美元，預計2026年將成長至499.7億美元，複合年成長率為9.57%，到2032年將達到867.8億美元。

主要市場統計數據
基準年 2025 457.4億美元
預計年份：2026年 499.7億美元
預測年份 2032 867.8億美元
複合年成長率 (%) 9.57%

在不斷變化的全球健康需求和技術進步的背景下，為動物用藥品的策略成長奠定基礎。

全球動物用藥品產業正處於關鍵轉折點，消費者行為的改變、疾病情勢的演變以及技術的突破正在重塑傳統的市場動態。新興市場對優質蛋白質來源的需求不斷成長，推動了對畜牧業健康解決方案前所未有的投資；同時，寵物飼養量的增加和預防性護理支出的成長也持續惠及伴侶動物護理行業。此外，人們對通用感染疾病的認知不斷提高，迫使相關人員加快研發疫苗和診斷方法，以保護動物和人類的健康。

揭示推動全球獸醫市場動物療法開發和交付模式轉移的因素。

隨著精準醫療、數位診斷和新型生技藥品重塑治療模式，獸醫領域正經歷著改變。次單位疫苗和減毒疫苗等先進疫苗平台展現出卓越的安全性和免疫抗原性，迫使生產者重新思考傳統方法。同時，遠端醫療和基於感測器的監測技術的融合實現了疾病的即時監測，有助於早期療育，並最終降低治療成本。

評估美國關稅政策在 2025 年對動物用藥品市場供應、價格壓力和策略重組的多層次影響。

2025年，美國對主要動物用藥品進口產品徵收多層關稅，將給整個供應鏈帶來新的成本壓力，迫使製造商重新思考其活性成分的籌資策略。抗生素、荷爾蒙和疫苗佐劑的供應商面臨利潤空間被壓縮的困境，相關人員正在探索替代貿易夥伴關係和近岸外包方案。因此，為了緩解關稅造成的價格波動，國內產能正透過資本投資和本地生產合約進行擴張。

我們將對產品、目標動物、給藥途徑、疾病、最終用戶和分銷管道等各個方面進行詳細分析，以確定策略性細分機會。

詳細的細分分析揭示了產品系列中的關鍵差異，傳統類別（如麻醉劑和抗發炎藥物）與快速成長的生物製藥和標靶驅蟲藥並存。抗生素仍發揮著至關重要的作用，但其分類日益細分為Fluoroquinolones、大環內酯類、青黴素類、磺胺類藥物和四環黴素，反映了治療應用的細微差別。同時，驅蟲策略也在不斷發展，力求在頻譜驅蟲藥和特異性體外寄生蟲控制藥物之間取得療效平衡；而去活化疫苗、減毒活病毒疫苗和次單位疫苗則在安全性、成本和免疫反應等方面展開競爭。

了解美洲、歐洲、中東和非洲以及亞太地區的趨勢，以推動市場擴張並開發個人化的獸醫解決方案。

美洲地區的趨勢持續受到健全的研究基礎設施、清晰的監管流程以及高昂的單隻動物投入的影響。尤其是在北美，大規模畜牧養殖和成熟的伴侶動物市場並存。關鍵在於，基於區塊鏈的可追溯性和一體化低溫運輸物流等供應鏈創新正在提高透明度、減少廢棄物並進一步提升市場效率。在拉丁美洲，乳製品和牛肉產業的擴張推動了人們對經濟高效的非專利藥和社區疫苗接種舉措的日益關注。

動物用藥品創新領導者概況：了解其競爭定位、合作趨勢及在發展顛覆性策略

動物用藥品市場的領導地位由生態系統構成，該系統由行業巨頭、高度專業化的中型企業和靈活的生物技術公司組成。老字型大小企業利用其強大的研發開發平臺，推動下一代疫苗、單株抗體和長效注射劑的開發，以應對抗生素抗藥性和跨物種通用感染疾病等緊迫挑戰。同時，中型企業專注於高利潤領域，例如馬匹治療、精準寄生蟲控制產品和個人化營養補充劑，從而在細分市場中佔據一席之地。

產業領導者面臨的策略挑戰包括：應對複雜的監管環境、利用技術進步以及最佳化價值鏈。

產業領導者應優先將數位健康工具融入其全球商業化策略。投資遠距遠端醫療平台、感測器驅動的診斷技術和數據分析解決方案，不僅能改善治療效果，還能打造差異化的服務產品，進而加深客戶參與。此外，與生物技術Start-Ups建立策略合作夥伴關係，將加速獲取基因編輯和合成生物學等創新平台，確保持續將突破性治療方法納入其產品組合。

概述了支持對全球動物用藥品市場進行全面分析的嚴謹的定性和定量方法。

本分析基於嚴謹的調查方法，該方法融合了定性和定量研究手段。主要研究工作包括對動物用藥品生產商的高階主管、監管專家、供應鏈經理和學術研究人員進行深入訪談。透過這些對話，我們獲得了關於新興趨勢、策略重點和營運挑戰的第一手觀點。

整合關鍵見解，引導相關人員走向不斷發展的全球動物用藥品生態系統的未來。

在本執行摘要中，我們檢驗了重塑動物用藥品產業的許多複雜因素，包括不斷變化的消費者需求、監管改革、技術突破以及地緣政治逆風。這些相互交織的因素凸顯了相關人員採取靈活策略、利用創新成果以及增強價值鏈韌性的必要性。市場領導必須追求差異化的價值提案，同時密切注意貿易政策和不斷變化的疾病模式所帶來的成本壓力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：動物用藥品市場：依產品類型分類

  • 麻醉劑
  • 抗發炎藥
  • 抗生素
    • Fluoroquinolones
    • 大環內酯類
    • 青黴素
    • 磺胺類藥物藥物
    • 四環黴素
  • 荷爾蒙和生長調節劑
  • 殺蟲劑
    • 驅蟲
    • 體外寄生蟲控制劑
  • 疫苗
    • 去活化疫苗
    • 減毒活病毒疫苗
    • 次單位疫苗

第9章動物用藥品市場：依類型分類

  • 水生動物
  • 鳥類
  • 伴侶動物
    • 貓
    • 狗
    • 馬
  • 家畜
    • 牛
    • 家禽
    • 綿羊/山羊
    • 豬
  • 野生動物

第10章：動物用藥品市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 液體
    • 粉末
    • 藥片
  • 腸外
  • 外用
    • 奶油
    • 軟膏
    • 噴

第11章動物用藥品市場：依疾病類型分類

  • 感染疾病
    • 細菌感染疾病
    • 黴菌感染疾病
    • 寄生蟲病
    • 病毒感染疾病
  • 非感染疾病
    • 發炎性疾病
    • 代謝性疾病
    • 營養缺乏
    • 生殖疾病

第12章：動物用藥品市場：依最終用戶分類

  • 政府和公共衛生機構
  • 畜牧場及家禽養殖場
  • 寵物飼主
  • 研究機構
  • 動物醫院和動物醫療機構

第13章：動物用藥品市場：依通路分類

  • 物理藥房
  • 網路藥房

第14章動物用藥品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：動物用藥品市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章動物用藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國動物用藥品市場

第18章：中國動物用藥品市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aurora Pharmaceutical, Inc.
  • Biogenesis Bago SA
  • Biovac Ltd.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chanelle Pharma
  • China Animal Husbandry Industry Co., Ltd.
  • Dechra Pharmaceuticals PLC
  • ECO Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • Huvepharma, Inc.
  • Indian Immunologicals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Laboratorio Drag Pharma Chile Invetec SA
  • Merck & Co., Inc.
  • Neogen Corporation
  • Nippon Zenyaku Kogyo Co., Ltd.
  • Norbrook Group
  • Orion Corporation
  • PetIQ, LLC
  • Phibro Animal Health Corporation
  • Teknofarma Srl
  • Veterinary Pharmaceutical Solutions
  • Vetoquinol Group
  • Vetpharma Animal Health SL by Insud Pharma SLU
  • Virbac SA
  • Zendal Group
  • Zoetis Inc.
Product Code: MRR-434CCDA05128

The Animal Pharmaceuticals Market was valued at USD 45.74 billion in 2025 and is projected to grow to USD 49.97 billion in 2026, with a CAGR of 9.57%, reaching USD 86.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 45.74 billion
Estimated Year [2026] USD 49.97 billion
Forecast Year [2032] USD 86.78 billion
CAGR (%) 9.57%

Laying the Groundwork for Strategic Growth in Animal Pharmaceuticals Amidst Evolving Global Health Demands and Technological Advancements

The global animal pharmaceuticals sector stands at a pivotal juncture as shifting consumer behaviors, evolving disease profiles, and technological breakthroughs converge to reshape traditional market dynamics. Intensifying demand for high-quality protein sources in emerging economies is driving unprecedented investment in livestock health solutions, while companion animal care continues to benefit from rising pet ownership and increasing expenditures on preventive therapies. Furthermore, heightened awareness of zoonotic disease transmission is compelling stakeholders to accelerate research into vaccines and diagnostics that protect both animal and human health.

Amid these trends, regulatory agencies worldwide are streamlining approval pathways for innovative biologics, antimicrobial agents, and point-of-care diagnostics. Public-private partnerships are emerging to combat antimicrobial resistance, while venture capital initiatives are fueling startups to explore gene editing, precision dosing, and digital health platforms. These developments underscore the importance of a multi-faceted strategy that balances the need for rapid product development with stringent safety and efficacy standards.

Accordingly, industry leaders must ground their growth plans in robust market intelligence that captures complex value chains, evolving regulatory frameworks, and shifting epidemiological patterns. By aligning R&D pipelines with emerging customer needs and leveraging cross-sector collaborations, stakeholders can unlock sustainable growth and build resilience against future disruptions.

Uncovering the Forces Driving a Paradigm Shift in Animal Health Treatment Development and Delivery Across Global Veterinary Markets

The animal health landscape is witnessing transformative shifts as precision medicine, digital diagnostics, and novel biologics redefine treatment paradigms. Advanced vaccine platforms, including subunit and attenuated modalities, are demonstrating superior safety profiles and immunogenicity, driving manufacturers to re-evaluate traditional approaches. Meanwhile, the integration of telemedicine and sensor-based monitoring is enabling real-time disease surveillance, facilitating earlier intervention and reducing overall treatment costs.

Moreover, growing concerns around antimicrobial resistance have accelerated interest in alternative therapies such as phage therapy, probiotics, and host-directed immunomodulators. Companies are forging alliances with academic institutions to fast-track these innovations through collaborative research and pooled expertise. In parallel, artificial intelligence and machine learning models are being deployed to optimize dosage regimens and forecast disease outbreaks based on environmental and genetic risk factors.

Consequently, organizations that embrace these disruptive technologies while maintaining a strong focus on regulatory compliance and cost-effectiveness will be best positioned to capture emerging market segments. Building flexible supply networks and investing in agile manufacturing processes will further enable rapid scale-up of production, ensuring timely delivery of next-generation therapies to meet evolving veterinary needs.

Assessing the Layered Effects of 2025 US Tariff Policies on Supply, Pricing Pressure, and Strategic Realignment in the Animal Pharmaceuticals Market

In 2025, the imposition of layered US tariffs on key animal pharmaceutical imports has introduced new cost pressures throughout the supply chain, compelling manufacturers to reassess sourcing strategies for active pharmaceutical ingredients. Suppliers of antibiotics, hormones, and vaccine adjuvants have experienced margin compression, prompting stakeholders to explore alternative trade partnerships and near-shoring options. As a result, domestic production capabilities are being expanded through capacity investments and localized manufacturing agreements to mitigate tariff-induced price volatility.

Furthermore, higher import duties have led to downstream pricing adjustments that influence end-user purchasing behavior, with veterinary clinics and farms increasingly seeking value-based contracts and bundled service offerings. This shift is accelerating the adoption of generic formulations and biosimilars in regions where cost sensitivity remains high. At the same time, premium markets with strong veterinary infrastructure continue to exhibit willingness to pay for innovative biologics and advanced diagnostics.

Accordingly, agile supply chain management and proactive regulatory engagement are paramount. Organizations that secure diversified raw material sources, negotiate long-term procurement agreements, and establish in-country fill-finish capabilities will build resilience against future trade disruptions. Embracing digital supply chain visibility tools and advanced analytics will further empower decision-makers to respond swiftly to shifting tariff landscapes and maintain competitive pricing.

Delving into Product, Species, Administration, Disease, End User, and Channel Dimensions to Reveal Strategic Segmentation Opportunities

Deep segmentation analysis reveals critical differentiation within the product portfolio, where traditional categories such as anesthetics and anti-inflammatory medications coexist with fast-growing biologic vaccines and targeted parasiticides. Antibiotics maintain a prominent role but are increasingly stratified across fluoroquinolones, macrolides, penicillins, sulfonamides, and tetracyclines, reflecting nuanced therapeutic applications. At the same time, parasiticide strategies are evolving to balance efficacy between broad-spectrum anthelmintics and specialized ectoparasiticides, while inactivated vaccines, live attenuated vaccines, and subunit vaccines compete on the basis of safety, cost, and immune response.

Equally important is the species dimension, where treatments for aquatic animals, birds, companion animals such as cats, dogs, and horses, livestock including cattle, poultry, sheep and goats, and swine, as well as wild animal care, present unique pharmacological and delivery challenges. Route of administration further refines market opportunities, as oral solutions in capsules, liquids, powders, and tablets offer convenience but face bioavailability constraints, while parenteral interventions dominate acute care and topical formulations in creams, ointments, and sprays address localized conditions. Disease type segmentation divides interventions between infectious diseases, encompassing bacterial, fungal, parasitic, and viral infections, and non-infectious disorders that range from inflammatory diseases to metabolic, nutritional, and reproductive disorders. End-user profiles complete the landscape, where government and public health bodies, livestock and poultry farms, pet owners, research institutions, and veterinary clinics and hospitals each demonstrate distinct procurement criteria. Finally, the channel dimension highlights the rising influence of online pharmacies alongside established offline pharmacy networks, signaling a shift in distribution strategies.

Mapping Regional Dynamics in Americas, EMEA, and Asia-Pacific to Guide Market Expansion and Tailored Veterinary Health Solutions

Regional dynamics in the Americas continue to be shaped by robust research infrastructure, well-defined regulatory pathways, and high per-animal expenditure, particularly in North America where large-scale livestock operations and sophisticated companion animal markets coexist. Importantly, supply chain innovations such as blockchain-enabled traceability and integrated cold-chain logistics are enhancing transparency and reducing spoilage, further bolstering market efficiency. In Latin America, expanding dairy and beef industries are driving interest in cost-effective generic therapeutics and community vaccination initiatives.

Across Europe, Middle East, and Africa, heterogeneous regulatory frameworks present both challenges and opportunities. EU member states emphasize stringent safety and environmental standards, spurring investment in next-generation biologics and antimicrobial stewardship programs. Meanwhile, Middle Eastern markets are witnessing an uptick in private veterinary services and demand for premium companion animal products. In Africa, emerging economies are prioritizing zoonotic disease control through public health campaigns and donor-funded vaccine distribution, highlighting the need for low-cost, thermostable formulations.

Asia-Pacific stands out for its dual landscape of rapidly modernizing production hubs and diverse disease burdens. Countries with advanced manufacturing capacity, such as Japan and South Korea, continue to lead innovation in precision biologics, while China and India are scaling up generic production to serve domestic and export markets. Southeast Asian nations are increasingly focused on aquaculture health solutions, reflecting the region's significant contribution to global fish protein supply. These varied regional profiles underscore the importance of tailored market entry and product strategies.

Profiling Leading Animal Health Innovators to Understand Competitive Positioning, Collaborative Trends, and Pipeline Disruption Strategies

Market leadership in animal pharmaceuticals is characterized by an ecosystem of industry giants, specialized mid-tier players, and agile biotechnology firms. Established corporations are leveraging their deep R&D pipelines to advance next-generation vaccines, monoclonal antibodies, and long-acting injectables that address pressing challenges such as antimicrobial resistance and cross-species zoonotic threats. Meanwhile, mid-sized companies are carving out niche positions by focusing on high-margin segments such as equine therapeutics, precision parasiticides, and bespoke nutritional supplements.

Collaborative partnerships are reshaping the competitive landscape, as alliances between multinational firms and academic spin-offs accelerate translational research. Licensing agreements for proprietary adjuvants and novel delivery technologies are becoming increasingly common, enabling smaller innovators to scale their solutions through established global networks. In addition, strategic M&A activity highlights a trend toward consolidating complementary capabilities, with acquirers seeking to bolster biologics platforms and digital health offerings. These moves are redefining traditional market hierarchies and setting new benchmarks for value creation.

Strategic Imperatives for Industry Leaders to Navigate Regulatory Complexity, Leverage Technological Advances, and Optimize Value Chains

Industry leaders must prioritize the integration of digital health tools into their global commercialization strategies. Investing in telemedicine platforms, sensor-enabled diagnostics, and data analytics solutions will not only enhance treatment outcomes but also create differentiated service offerings that deepen customer engagement. Furthermore, forging strategic alliances with biotechnology startups can accelerate access to innovative platforms such as gene editing and synthetic biology, ensuring a continuous flow of disruptive therapies into the portfolio.

Regulatory engagement should be elevated from a compliance function to a proactive strategic capability. By participating in policy dialogues, contributing to antimicrobial stewardship guidelines, and advocating for harmonized approval pathways, organizations can shape favorable environments for advanced biologics and novel modalities. Finally, building supply chain resilience through diversified sourcing, in-country manufacturing partnerships, and digital traceability systems will safeguard against future trade disruptions and strengthen market responsiveness.

Outlining Rigorous Qualitative and Quantitative Approaches Underpinning Comprehensive Analysis of the Global Animal Pharmaceuticals Landscape

This analysis is founded on a rigorous research methodology that integrates both qualitative and quantitative approaches. Primary research included in-depth interviews with senior executives at veterinary pharmaceutical manufacturers, regulatory experts, supply chain managers, and academic researchers. These conversations provided firsthand perspectives on emerging trends, strategic priorities, and operational challenges.

Secondary research encompassed an exhaustive review of scientific literature, regulatory filings, patent databases, and industry publications. Market dynamics were further validated through proprietary data sets and trade statistics, while competitive landscapes were mapped using detailed product registries and company disclosures. All data points underwent cross-verification to ensure accuracy and relevance, and insights were synthesized through collaborative workshops with subject-matter experts. This robust methodology underpins the credibility and depth of our findings.

Synthesizing Critical Findings to Chart a Path Forward for Stakeholders in the Evolving Global Veterinary Pharmaceuticals Ecosystem

Throughout this executive summary, we have navigated the intricate forces reshaping the animal pharmaceuticals industry, from shifting consumer demands and regulatory reforms to technological breakthroughs and geopolitical headwinds. The convergence of these factors underscores the necessity for stakeholders to adopt agile strategies, harness emerging innovations, and strengthen supply chain resilience. As market leaders pursue differentiated value propositions, they must remain vigilant to cost pressures introduced by trade policies and evolving disease patterns.

Looking ahead, sustained growth will depend on the ability to balance investment across core segments such as antibiotics, vaccines, and parasiticides while exploring frontier areas including precision biologics, digital health, and alternative therapeutics. By embedding a culture of continuous innovation and proactive collaboration, organizations can position themselves to meet the complex health needs of diverse animal populations and drive sustainable value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Pharmaceuticals Market, by Product Type

  • 8.1. Anesthetics
  • 8.2. Anti-Inflammatory Medications
  • 8.3. Antibiotics
    • 8.3.1. Fluoroquinolones
    • 8.3.2. Macrolides
    • 8.3.3. Penicillins
    • 8.3.4. Sulfonamides
    • 8.3.5. Tetracyclines
  • 8.4. Hormones & Growth Regulators
  • 8.5. Parasiticides
    • 8.5.1. Anthelmintics
    • 8.5.2. Ectoparasiticides
  • 8.6. Vaccines
    • 8.6.1. Inactivated Vaccines
    • 8.6.2. Live Attenuated Vaccines
    • 8.6.3. Subunit Vaccines

9. Animal Pharmaceuticals Market, by Species

  • 9.1. Aquatic Animals
  • 9.2. Birds
  • 9.3. Companion Animals
    • 9.3.1. Cats
    • 9.3.2. Dogs
    • 9.3.3. Horses
  • 9.4. Livestock Animals
    • 9.4.1. Cattle
    • 9.4.2. Poultry
    • 9.4.3. Sheep & Goats
    • 9.4.4. Swine
  • 9.5. Wild Animals

10. Animal Pharmaceuticals Market, by Route of Administration

  • 10.1. Oral
    • 10.1.1. Capsules
    • 10.1.2. Liquid solutions
    • 10.1.3. Powders
    • 10.1.4. Tablets
  • 10.2. Parenteral
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Ointments
    • 10.3.3. Sprays

11. Animal Pharmaceuticals Market, by Disease Type

  • 11.1. Infectious Diseases
    • 11.1.1. Bacterial Infections
    • 11.1.2. Fungal Infections
    • 11.1.3. Parasitic Infestations
    • 11.1.4. Viral Infections
  • 11.2. Non-Infectious Diseases
    • 11.2.1. Inflammatory Diseases
    • 11.2.2. Metabolic Disorders
    • 11.2.3. Nutritional Deficiencies
    • 11.2.4. Reproductive Disorders

12. Animal Pharmaceuticals Market, by End User

  • 12.1. Government & Public Health Organizations
  • 12.2. Livestock Farms & Poultry Farms
  • 12.3. Pet Owners
  • 12.4. Research Institutions
  • 12.5. Veterinary Clinics & Hospitals

13. Animal Pharmaceuticals Market, by Distribution Channels

  • 13.1. Offline Pharmacies
  • 13.2. Online Pharmacies

14. Animal Pharmaceuticals Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Animal Pharmaceuticals Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Animal Pharmaceuticals Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Animal Pharmaceuticals Market

18. China Animal Pharmaceuticals Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aurora Pharmaceutical, Inc.
  • 19.6. Biogenesis Bago S.A.
  • 19.7. Biovac Ltd.
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Ceva Sante Animale
  • 19.10. Chanelle Pharma
  • 19.11. China Animal Husbandry Industry Co., Ltd.
  • 19.12. Dechra Pharmaceuticals PLC
  • 19.13. ECO Animal Health Group PLC
  • 19.14. Elanco Animal Health Incorporated
  • 19.15. Hester Biosciences Limited
  • 19.16. Huvepharma, Inc.
  • 19.17. Indian Immunologicals Ltd.
  • 19.18. Intas Pharmaceuticals Ltd.
  • 19.19. Laboratorio Drag Pharma Chile Invetec S.A.
  • 19.20. Merck & Co., Inc.
  • 19.21. Neogen Corporation
  • 19.22. Nippon Zenyaku Kogyo Co., Ltd.
  • 19.23. Norbrook Group
  • 19.24. Orion Corporation
  • 19.25. PetIQ, LLC
  • 19.26. Phibro Animal Health Corporation
  • 19.27. Teknofarma S.r.l.
  • 19.28. Veterinary Pharmaceutical Solutions
  • 19.29. Vetoquinol Group
  • 19.30. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
  • 19.31. Virbac S.A.
  • 19.32. Zendal Group
  • 19.33. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 311. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN ANIMAL PHARMACEUTICALS MARKET SI